UA138100U - METHOD FOR PREDICTING THE DEVELOPMENT OF OSTEOARTHRITIS - Google Patents

Abstract

The method of predicting the development of osteoarthritis includes clinical examination, radiography. Additionally, in the patient's serum determine the polymorphism of the gene for methylenetetrahydrofolate reductase (MTHFR C677T), the content of thrombomodulin, glycosaminoglycans (GAG), homocysteine, C-reactive protein (PSA) and at a homozygous level. μmol / l, homocysteine> 20 μmol / l, PSA> 6 mg / l predict the development of osteoarthritis.

Description

A useful model for predicting the development of osteoarthritis belongs to medicine, in particular to orthopedics and rheumatology. It is prescribed and can be used in diagnosing the development of osteoarthritis in the early stages.

Methods of predicting the development of osteoarthritis are known. These include x-rays, examination of biopsies of the synovial membrane, synovial fluid, and cartilage biopsies (A.N.

Okorokov Diagnosis of diseases of internal organs. M., 2001. - vol. 2. - pp. 186-196). The disadvantage of these methods is the lack of the possibility of predicting the dynamics of the process in the early subclinical stages, preventing its development and possible complications due to the internal characteristics of the body.

The basis of a useful model is the task of developing a method that would allow predicting the development of osteoarthritis in the early stages.

The task is solved by the fact that the method of predicting the development of osteoarthritis includes clinical examination and radiography. In addition, the polymorphism of the methylenetetrahydrofolate reductase gene (MITNEK C677T), the content of thrombomodulin, glycosaminoglycans (GAG), homocysteine, C-reactive protein (CRP) and homozygous carrier 677-TT and levels of thrombomodulin »5 ng/ml, GAG »28 are determined in the patient's blood serum. μmol/l, homocysteine 220 μmol/l, SRP 26 mg/l predict the development of osteoarthritis.

Application of the method. Upon admission, the patient is examined, an X-ray is taken, and the MTNEK S677T gene polymorphism is determined. The content of thrombomodulin, GAG, homocysteine, SRP is determined by the immunoenzymatic method. With homozygous carrier 677-TT, levels of thrombomodulin »5 ng/ml, GAG »28 μmol/l, homocysteine »20 μmol/l, SRP »b mg/l predict the development of osteoarthritis.

A specific example of using the method.

Patient A., 59 years old, was admitted to the clinic due to pain in the left hip joint. Examined, X-ray taken. No signs of osteoarthritis were found. The MTNEK C611T gene polymorphism was determined in blood serum. The content of thrombomodulin, GAG, homocysteine, SRP was determined by immunoenzymatic method. Homozygous carrier 677-TT was established. Thrombomodulin levels - 10 ng/ml, GAG - 37 μmol/l, homocysteine - 30 μmol/l, PSA - 12 mg/l.

The development of osteoarthritis was diagnosed. After 11 months, X-rays revealed phenomena

Koo) osteoarthritis.

Thus, the proposed method is informative and allows diagnosing the development of osteoarthritis at an early stage.

Claims (1)

USEFUL MODEL FORMULA The method of predicting the development of osteoarthritis, which includes a clinical examination, radiography, which is distinguished by the fact that, in addition, in the patient's blood serum, the polymorphism of the methylenetetrahydrofolate reductase gene (MTNEK C677T), the content of thrombomodulin, glycosaminoglycans (GAG), homocysteine, C-reactive protein (CRP) and homozygous carrier 677-171 and levels of thrombomodulin »5 ng/ml, GAG »28 μmol/l, homocysteine 220 μmol/l, PSA »6 mg/l predict the development of osteoarthritis.